These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 25726736)
1. Is obeticholic Acid the solution to nonalcoholic steatohepatitis? Wong VW; Wong GL; Chan FK Gastroenterology; 2015 Apr; 148(4):851-2. PubMed ID: 25726736 [No Abstract] [Full Text] [Related]
2. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns. Polyzos SA; Kountouras J; Mantzoros CS Metabolism; 2020 Mar; 104():154144. PubMed ID: 31930974 [No Abstract] [Full Text] [Related]
4. Trials of obeticholic acid for non-alcoholic steatohepatitis. Musso G; Cassader M; Gambino R Lancet; 2015 Jul; 386(9988):27. PubMed ID: 26169860 [No Abstract] [Full Text] [Related]
5. Trials of obeticholic acid for non-alcoholic steatohepatitis - Authors' reply. Neuschwander-Tetri BA; Van Natta ML; Tonascia J; Brunt EM; Kleiner DE Lancet; 2015 Jul; 386(9988):28-29. PubMed ID: 26169861 [No Abstract] [Full Text] [Related]
6. Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost. Musso G Hepatology; 2015 Jun; 61(6):2104-6. PubMed ID: 25753820 [No Abstract] [Full Text] [Related]
7. NAFLD: obeticholic acid for the treatment of fatty liver disease--NASH no more? Ray K Nat Rev Gastroenterol Hepatol; 2015 Jan; 12(1):1. PubMed ID: 25421586 [No Abstract] [Full Text] [Related]
8. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Gawrieh S; Chalasani N Clin Liver Dis; 2018 Feb; 22(1):189-199. PubMed ID: 29128056 [TBL] [Abstract][Full Text] [Related]
9. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease. Makri E; Cholongitas E; Tziomalos K World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393 [TBL] [Abstract][Full Text] [Related]
10. Obeticholic acid: expanding the therapeutic landscape of NASH. Arrese M; Cabrera D; Barrera F Ann Hepatol; 2015; 14(3):430-2. PubMed ID: 25864227 [No Abstract] [Full Text] [Related]
11. Starting the battle to control non-alcoholic steatohepatitis. Ratziu V Lancet; 2015 Mar; 385(9972):922-4. PubMed ID: 25468161 [No Abstract] [Full Text] [Related]
12. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Singh S; Khera R; Allen AM; Murad MH; Loomba R Hepatology; 2015 Nov; 62(5):1417-32. PubMed ID: 26189925 [TBL] [Abstract][Full Text] [Related]
13. The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives. Gitto S; Guarneri V; Sartini A; Andreone P Expert Rev Gastroenterol Hepatol; 2018 Feb; 12(2):165-171. PubMed ID: 29082798 [TBL] [Abstract][Full Text] [Related]
14. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Adorini L; Pruzanski M; Shapiro D Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341 [TBL] [Abstract][Full Text] [Related]